Suchergebnisse - "Clinical Trial, Phase III"

PubPharm (629)

1

Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

enthalten in: The New England journal of medicine | 2024

von Munir, T. | Cairns, D. | Bloor, A. | +121

2

R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK) : final results of a multicentre, phase 3, open-label, randomised trial

enthalten in: The Lancet. Haematology | 2023

von Chamuleau, M. | Stenner, F. | Chitu, D. | +28

3

Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19) : quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

enthalten in: The Lancet. Oncology | 2023

von Velikova, G. | Morden, J. | Haviland, J. | +15

ErratumIn: Lancet Oncol. 2023 Dec;24(12):e459. - PMID 38040001

4

Busulfan Plus Fludarabine Compared With Busulfan Plus Cyclophosphamide for AML Undergoing HLA-Haploidentical Hematopoietic Cell Transplantation : A Multicenter Randomized Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2023

von Ling, Y. | Xuan, L. | Xu, N. | +20

5

Randomized phase III trial of a neoadjuvant regimen of four cycles of adriamycin plus cyclophosphamide followed by four cycles of docetaxel (AC4-D4) versus a shorter treatment of three cycles of FEC followed by three cycles of docetaxel (FEC3-D3) in node-positive breast cancer (Neo-shorter; NCT02001506)

enthalten in: Breast cancer research and treatment | 2023

von Hwang, I. | Kim, J. | Jeong, J. | +8

6

Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma

enthalten in: Blood advances | 2023

von Burack, W. | Li, H. | Adlowitz, D. | +9

7

Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis

enthalten in: The New England journal of medicine | 2023

von Bolaños-Meade, J. | Hamadani, M. | Wu, J. | +69

8

Detailed Sub-study Analysis of the SECRAB Trial : Quality of Life, Cosmesis and Chemotherapy Dose Intensity

enthalten in: Clinical oncology (Royal College of Radiologists (Great Britain)) | 2023

von Fernando, I. | Lax, S. | Bowden, S. | +8

9

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

enthalten in: The New England journal of medicine | 2023

von Eichhorst, B. | Niemann, C. | Kater, A. | +148

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):503. - PMID 37237098

10

Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR) : interim analysis of a multicentre, open-label, randomised, phase 3 trial

enthalten in: The Lancet. Oncology | 2023

von Hillmen, P. | Pitchford, A. | Bloor, A. | +29

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[63]